Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Bollard, Catherine M  [Clear All Filters]
2013
Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJN, Decker WK, Li S, Robinson SN, Sekine T, et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013;8(10):e76781.
Russell Y Cruz C, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, A Barrett J, Ito S, et al. Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study. Blood. 2013.
Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai S-Y, Rowley SD, Kebriaei P, et al. Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013.
2014
Hanley PJ, Bollard CM. Controlling cytomegalovirus: helping the immune system take the lead. Viruses. 2014;6(6):2242-58.
Bollard CM, A Barrett J. Cytotoxic T lymphocytes for leukemia and lymphoma. Hematology Am Soc Hematol Educ Program. 2014;2014(1):565-569.
2015
Hanley PJ, Bollard CM, Brunstein CG. Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood. Cytotherapy. 2015.
LaVoy ECP, Bollard CM, Hanley PJ, Blaney JW, O'Connor DP, Bosch JA, Simpson RJ. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults. Exerc Immunol Rev. 2015;21:144-153.
2018
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, et al. Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl. Biol Blood Marrow Transplant. 2018.
2021
Saldaña BJDávila, John TD, Bonifant CL, Buchbinder D, Chandra S, Chandrakasan S, Chang W, Chen L, Elfassy HL, Geerlinks AV, et al. High risk of relapsed disease in patients with NK/T cell chronic active Epstein-Barr virus disease outside of Asia. Blood Adv. 2021.
2022
Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray LM, Thomas S, Dourson C, Wilhelm J, Lane A, et al. Scheduled Administration of Virus-Specific T cells for Viral Prophylaxis After Pediatric Allogeneic Stem Cell Transplant. Blood Adv. 2022.
2023
Kitko CL, Bollard CM, Cairo MS, Chewning J, Fry TJ, Pulsipher MA, Shenoy S, Wall DA, Levine JE. Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation. Pediatr Blood Cancer. 2023:e30577.
Alexander S, Auperin A, Bomken S, Csóka M, Kazanowska B, Chiang AK, Andres M, Uyttebroeck A, Burke A, Zsiros J, et al. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. Lancet Haematol. 2023.
Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YZM, Hanley PJ, Keller MD, Bollard CM, et al. Third party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplant in children and young adults. Transplant Cell Ther. 2023.
2024
Vittayawacharin P, Kongtim P, Chu Y, June CH, Bollard CM, Ciurea SO. Adoptive cellular therapy after hematopoietic stem cell transplantation. Am J Hematol. 2024.
Keller MD, Hanley PJ, Chi Y-Y, Aguayo-Hiraldo P, Dvorak CC, Verneris MR, Kohn DB, Pai S-Y, Saldaña BJDávila, Hanisch B, et al. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Nat Commun. 2024;15(1):3258.
Khoury R, Grimley MS, Nelson AS, Leemhuis T, Cancelas JA, Cook E, Wang YZ, Heyenbruch D, Bollard CM, Keller MD, et al. Third-party virus specific T cells for the treatment of double stranded DNA viral reactivation and PTLD after solid organ transplant. Am J Transplant. 2024.